Piers Blombery
@pbmd99.bsky.social
Clinical and Laboratory Haematologist, Peter MacCallum Cancer Centre
Lead of Wilson Centre for Blood Cancer Genomics
Lead of Wilson Centre for Blood Cancer Genomics
Reposted by Piers Blombery
Two patients with refractory myeloma who had excellent antitumor responses to cilta-cel CAR T-cell therapy later had T-cell lymphomas that contained the lentivirus construct used to generate the CAR T-cell product. Brief Report on the CARTITUDE-4 trial: nej.md/4gA6G27
#MedSky #Hematology
#MedSky #Hematology
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma | NEJM
We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel (cil...
nej.md
February 12, 2025 at 10:30 PM
Two patients with refractory myeloma who had excellent antitumor responses to cilta-cel CAR T-cell therapy later had T-cell lymphomas that contained the lentivirus construct used to generate the CAR T-cell product. Brief Report on the CARTITUDE-4 trial: nej.md/4gA6G27
#MedSky #Hematology
#MedSky #Hematology
Reposted by Piers Blombery
A recent case report from MSKCC published in the NEJM describes the development of a CD4+ T-cell lymphoma in a patient with multiple myeloma following B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy
has been described, but the contribution of CAR integration to oncogenesis is not
clear. Here we report a case o...
www.nejm.org
February 6, 2025 at 5:18 AM
A recent case report from MSKCC published in the NEJM describes the development of a CD4+ T-cell lymphoma in a patient with multiple myeloma following B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Reposted by Piers Blombery
A woman with multiply relapsed multiple myeloma had complete remission with cilta-cel, but a low-grade T-cell lymphoma soon developed in the GI tract that contained an insertion of the CAR construct disrupting expression of p53. Read the Brief Report: nej.md/40Yq3gO
#MedSky #Oncology
#MedSky #Oncology
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...
nej.md
February 7, 2025 at 6:13 PM
A woman with multiply relapsed multiple myeloma had complete remission with cilta-cel, but a low-grade T-cell lymphoma soon developed in the GI tract that contained an insertion of the CAR construct disrupting expression of p53. Read the Brief Report: nej.md/40Yq3gO
#MedSky #Oncology
#MedSky #Oncology
Attempt at putting what we know about #BTK resistance mutations into one figure..
Beware inducing cross-resistant L528Wmuts pre ncBTKi.
#hemesky #hematology #lymsm #hemepath #NGS
pubmed.ncbi.nlm.nih.gov/39808800/
Beware inducing cross-resistant L528Wmuts pre ncBTKi.
#hemesky #hematology #lymsm #hemepath #NGS
pubmed.ncbi.nlm.nih.gov/39808800/
January 25, 2025 at 8:18 AM
Attempt at putting what we know about #BTK resistance mutations into one figure..
Beware inducing cross-resistant L528Wmuts pre ncBTKi.
#hemesky #hematology #lymsm #hemepath #NGS
pubmed.ncbi.nlm.nih.gov/39808800/
Beware inducing cross-resistant L528Wmuts pre ncBTKi.
#hemesky #hematology #lymsm #hemepath #NGS
pubmed.ncbi.nlm.nih.gov/39808800/
Make sure you are testing for UBTF-TDs in paed MDS/AML (and adult MDS/AML!).
Morphological/immunophenotypic clues = dysplasia in paed AML, CD34/CD117 dim
Molecular clues = FLT3mut/WT1mut
Menin inhibition as potential therapeutic modality.
#hemesky #hemepath
journals.lww.com/ajsp/fulltex...
Morphological/immunophenotypic clues = dysplasia in paed AML, CD34/CD117 dim
Molecular clues = FLT3mut/WT1mut
Menin inhibition as potential therapeutic modality.
#hemesky #hemepath
journals.lww.com/ajsp/fulltex...
Pediatric Myeloid Neoplasms With UBTF Tandem Duplications:... : The American Journal of Surgical Pathology
e of AML. To further our understanding of myeloid neoplasms with UBTF-TD, we analyzed clinical, morphologic, and immunophenotypic characteristics of 27 pediatric patients with UBTF-TD-positive myeloid...
journals.lww.com
January 8, 2025 at 3:19 AM
Make sure you are testing for UBTF-TDs in paed MDS/AML (and adult MDS/AML!).
Morphological/immunophenotypic clues = dysplasia in paed AML, CD34/CD117 dim
Molecular clues = FLT3mut/WT1mut
Menin inhibition as potential therapeutic modality.
#hemesky #hemepath
journals.lww.com/ajsp/fulltex...
Morphological/immunophenotypic clues = dysplasia in paed AML, CD34/CD117 dim
Molecular clues = FLT3mut/WT1mut
Menin inhibition as potential therapeutic modality.
#hemesky #hemepath
journals.lww.com/ajsp/fulltex...
CD274 3’UTR deletion and genomically hardwired #PDL1 over expression as an adaptive survival mechanism to #atezolizumab.. ?specific mechanism to targeting the tumour side of the immune synapse #hemesky #hemepath
doi.org/10.1080/1042...
doi.org/10.1080/1042...
Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma
Published in Leukemia & Lymphoma (Ahead of Print, 2024)
doi.org
December 27, 2024 at 7:33 AM
CD274 3’UTR deletion and genomically hardwired #PDL1 over expression as an adaptive survival mechanism to #atezolizumab.. ?specific mechanism to targeting the tumour side of the immune synapse #hemesky #hemepath
doi.org/10.1080/1042...
doi.org/10.1080/1042...
Reposted by Piers Blombery
What a joy it is to hear our very own Sant-Ryan Pasricha presenting Best of #ASH24. Who else could personalise this so much and use a picture of the hallowed ground of the @MCG (Melbourne Cricket Ground) to such good effect? Go Santa!
December 10, 2024 at 7:59 PM
What a joy it is to hear our very own Sant-Ryan Pasricha presenting Best of #ASH24. Who else could personalise this so much and use a picture of the hallowed ground of the @MCG (Melbourne Cricket Ground) to such good effect? Go Santa!
Therapy related myeloid neoplasm post CART in DLBCL arises from TP53 clones identifiable preCART… but high baseline incidence of TP53/PPM1D CH preCART.. so the challenge is identifying those with clones that will progress - Zhi Han Yeoh from @petermaccc.bsky.social. #ASH24 #hemepath #hemesky #lymsm
December 9, 2024 at 8:17 PM
Therapy related myeloid neoplasm post CART in DLBCL arises from TP53 clones identifiable preCART… but high baseline incidence of TP53/PPM1D CH preCART.. so the challenge is identifying those with clones that will progress - Zhi Han Yeoh from @petermaccc.bsky.social. #ASH24 #hemepath #hemesky #lymsm
Very interesting R-CHOP+X session (or Pola-R-CHP+X..) in DLBCL. 3/6 presentations in the session with data presented on ctDNA MRD!.. including the COALITION study (Adrian Minson/ @drmikedickinson.bsky.social. CtDNA helpful in resolving nature of EOT PET abnormalities #ASH24 #lymsm #hemesky #hemepath
December 9, 2024 at 5:47 PM
Very interesting R-CHOP+X session (or Pola-R-CHP+X..) in DLBCL. 3/6 presentations in the session with data presented on ctDNA MRD!.. including the COALITION study (Adrian Minson/ @drmikedickinson.bsky.social. CtDNA helpful in resolving nature of EOT PET abnormalities #ASH24 #lymsm #hemesky #hemepath
Reposted by Piers Blombery
Critical RW data, especially data re: better PFS for pola for non-GC in the post-CAR setting. Huge congratulations to Drs. Cliff and Russler-Germain for this tour de force, and for inviting us at @CULymphoma @CUHematology (and @JessicaAllenMD) to participate. #ASH24 #lymsm
December 9, 2024 at 3:19 AM
Reposted by Piers Blombery
Zoe McQuilten from Monash 🇦🇺presenting the final results of the Diaamond-AVA-first looking at hATG, CSA, and avatromboag. Similar results to eltrombopag seen. #ASH24 @ash-hematology.bsky.social
December 8, 2024 at 12:58 AM
Zoe McQuilten from Monash 🇦🇺presenting the final results of the Diaamond-AVA-first looking at hATG, CSA, and avatromboag. Similar results to eltrombopag seen. #ASH24 @ash-hematology.bsky.social
Dr. Jacoby from Washington University on intervening in AML based on mut clearance at 2.5% VAF across exome level in a variant agnostic way. Great to see this “fingerprint” MRD approach being used in trials.. lots of analogies to current lymphoma ctDNA space #hemepath #hemesky #leusm #lymsm #ASH24
December 7, 2024 at 11:40 PM
Exciting to see the first results from the INTERCEPT platform study (PI Andrew Wei) expertly presented by Dr. Sun Loo from @petermaccc.bsky.social at #ASH24. Intervening with a molecularly rational approach at early #MRD relapse is feasible in AML and the results with revumenib are encouraging.
December 7, 2024 at 11:25 PM
Exciting to see the first results from the INTERCEPT platform study (PI Andrew Wei) expertly presented by Dr. Sun Loo from @petermaccc.bsky.social at #ASH24. Intervening with a molecularly rational approach at early #MRD relapse is feasible in AML and the results with revumenib are encouraging.
Dr. Ing Soo Tiong from @petermaccc.bsky.social presenting his excellent work at #ASH24 on how the remission clonal haematopoietic landscape is shaped by venetoclax in pts with AML. TP53 and BAX microclones! With a bit more sensitive sequencing tech we will find the nanoclones… #hemepath #hemesky
December 7, 2024 at 7:17 PM
Dr. Ing Soo Tiong from @petermaccc.bsky.social presenting his excellent work at #ASH24 on how the remission clonal haematopoietic landscape is shaped by venetoclax in pts with AML. TP53 and BAX microclones! With a bit more sensitive sequencing tech we will find the nanoclones… #hemepath #hemesky
December 6, 2024 at 1:30 AM
Looking forward to the Germline Predisposition FSW at #ASH24… (check out summary at link below!). For those attending - make sure you stay to hear Sean Harrop present our work on germline #TET2 variants and an emerging novel syndrome..
#hemesky #hemepath #hematology
youtu.be/UEKszF06k2Y
#hemesky #hemepath #hematology
youtu.be/UEKszF06k2Y
ASH 2024 Friday Scientific Workshop on Germline Predisposition to Hematologic Malignancies and BMF
YouTube video by Marcin W
youtu.be
December 4, 2024 at 6:17 PM
Looking forward to the Germline Predisposition FSW at #ASH24… (check out summary at link below!). For those attending - make sure you stay to hear Sean Harrop present our work on germline #TET2 variants and an emerging novel syndrome..
#hemesky #hemepath #hematology
youtu.be/UEKszF06k2Y
#hemesky #hemepath #hematology
youtu.be/UEKszF06k2Y
Reposted by Piers Blombery
NGS variants prior to CAR #ASH24:
- 173 pts, 63% axi-cel
- 43% had CH prior to CAR: 54% DNMT3A, 26% TP53
- 6% developed MN: 3-yr cumulative incidence of 11% with death from LBCL as competing risk
- median time CAR to MN 25 mos
- CH➡️late thrombocytopenia after CAR #lymsm #bmtsm
- 173 pts, 63% axi-cel
- 43% had CH prior to CAR: 54% DNMT3A, 26% TP53
- 6% developed MN: 3-yr cumulative incidence of 11% with death from LBCL as competing risk
- median time CAR to MN 25 mos
- CH➡️late thrombocytopenia after CAR #lymsm #bmtsm
November 14, 2024 at 10:38 AM
Reposted by Piers Blombery
We recently joined forces with the University of Melbourne to create the Collaborative Centre for Genomic Cancer Medicine.
It's Director Prof Sean Grimmond and A/Prof David Westerman joined ABC Melbourne to talk about the new centre's mission and future of #genomicmedicine.
A fascinating listen!
It's Director Prof Sean Grimmond and A/Prof David Westerman joined ABC Melbourne to talk about the new centre's mission and future of #genomicmedicine.
A fascinating listen!
Why are scientists so excited about genomics? - ABC listen
Genomics explores the building blocks of human DNA, in the hopes of uncovering patterns that can lead to lifesaving medical discoveries.
www.abc.net.au
November 28, 2024 at 4:45 AM
We recently joined forces with the University of Melbourne to create the Collaborative Centre for Genomic Cancer Medicine.
It's Director Prof Sean Grimmond and A/Prof David Westerman joined ABC Melbourne to talk about the new centre's mission and future of #genomicmedicine.
A fascinating listen!
It's Director Prof Sean Grimmond and A/Prof David Westerman joined ABC Melbourne to talk about the new centre's mission and future of #genomicmedicine.
A fascinating listen!